Literature DB >> 33360851

Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.

Nicola R Jones1, Suzanne Nielsen2, Michael Farrell3, Robert Ali4, Anthony Gill5, Sarah Larney6, Louisa Degenhardt7.   

Abstract

BACKGROUND: There has been much research on the efficacy and effectiveness of opioid agonist treatment (OAT), but less on its implementation and sustainability. A challenge internationally has been recruiting and retaining prescribers. This paper aims to characterise the prescribers in terms of OAT prescribing behaviours.
METHODS: Retrospective cohort study in New South Wales, Australia. Participants were 2199 OAT prescribers between 1 st August 2001-19th September 2018.We examined trends in initiation and cessation of OAT prescribers. Adjusted hazard ratios were calculated to estimate prescriber retention, adjusting for year of initiation, practice type, client load and treatment prescribed.
RESULTS: The rate of prescribers ceasing OAT prescribing has been increasing over time: a prescriber who initiated between 2016-2017 had over four times the risk of cessation compared with one who initiated before 2001, AHR: 4.77; [3.67-6.21]. The highest prescriber cessation rate was in prescribers who had prescribed for shorter time periods. The annual percentage of prescribers who ceased prescribing among those who prescribed for ≤5 years increased from 3% in 2001 to 20 % in 2017. By 2017 more prescribers were discontinuing prescribing than new prescribers were starting. Approximately 87 % (n = 25,167) of OAT clients were under the care of 20 % of OAT prescribers (n = 202); half had been prescribing OAT for 17+ years.
CONCLUSIONS: OAT prescribing is increasingly concentrated in a small group of mature prescribers, and new prescribers are not being retained. There is a need to identify and respond to the reasons that contribute to newer prescribers to cease prescribing and put in place strategies to increase retention and broaden the base of doctors involved in such prescribing.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Buprenorphine; Methadone; Opioid agonist treatment; Opioid dependence; Prescriber; Retention

Mesh:

Substances:

Year:  2020        PMID: 33360851      PMCID: PMC7855715          DOI: 10.1016/j.drugalcdep.2020.108464

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

1.  General practice management of illicit drug users in Scotland: a national survey.

Authors:  C Matheson; J Pitcairn; C M Bond; E van Teijlingen; M Ryan
Journal:  Addiction       Date:  2003-01       Impact factor: 6.526

2.  The Pareto principle.

Authors:  P Erridge
Journal:  Br Dent J       Date:  2006-10-07       Impact factor: 1.626

3.  Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.

Authors:  Qi Guan; Wayne Khuu; Sheryl Spithoff; Tara Kiran; Meldon Kahan; Mina Tadrous; Diana Martins; Pamela Leece; Tara Gomes
Journal:  Drug Alcohol Depend       Date:  2017-07-19       Impact factor: 4.492

4.  Medication-assisted therapies--tackling the opioid-overdose epidemic.

Authors:  Nora D Volkow; Thomas R Frieden; Pamela S Hyde; Stephen S Cha
Journal:  N Engl J Med       Date:  2014-04-23       Impact factor: 91.245

5.  Building virtual communities of practice for health.

Authors:  Bruce Struminger; Sanjeev Arora; Sarah Zalud-Cerrato; David Lowrance; Tedd Ellerbrock
Journal:  Lancet       Date:  2017-08-12       Impact factor: 79.321

6.  Primary Care Physicians' Views about Prescribing Methadone to Treat Opioid Use Disorder.

Authors:  James D Livingston; Erica Adams; Marlee Jordan; Zachary MacMillan; Ramm Hering
Journal:  Subst Use Misuse       Date:  2017-08-30       Impact factor: 2.164

7.  French field experience with buprenorphine.

Authors:  Marc Auriacombe; Mélina Fatséas; Jacques Dubernet; Jean-Pierre Daulouède; Jean Tignol
Journal:  Am J Addict       Date:  2004

8.  A cohort study examining emergency department visits and hospital admissions among people who use drugs in Ottawa, Canada.

Authors:  Claire E Kendall; Lisa M Boucher; Amy E Mark; Alana Martin; Zack Marshall; Rob Boyd; Pam Oickle; Nicola Diliso; Dave Pineau; Brad Renaud; Tiffany Rose; Sean LeBlanc; Mark Tyndall; Olivia M Lee; Ahmed M Bayoumi
Journal:  Harm Reduct J       Date:  2017-05-12

9.  Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia.

Authors:  Briony Larance; Louisa Degenhardt; Jason Grebely; Suzanne Nielsen; Raimondo Bruno; Paul Dietze; Kari Lancaster; Sarah Larney; Thomas Santo; Marian Shanahan; Sonja Memedovic; Robert Ali; Michael Farrell
Journal:  Addiction       Date:  2020-02-05       Impact factor: 6.526

10.  Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study.

Authors:  Sarah Larney; Matthew Hickman; David A Fiellin; Timothy Dobbins; Suzanne Nielsen; Nicola R Jones; Richard P Mattick; Robert Ali; Louisa Degenhardt
Journal:  BMJ Open       Date:  2018-08-05       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.